Hot Pharma Stocks / Ideen / Blockbuster

    RNN

    Rexahn Awarded Qualifying Therapeutic Discovery Project Grants to Further Develop Anti-Cancer, Depression, and Erectile Dysfunction Treatments.




    Rockville, MD, November 4, 2010– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced today that it has been awarded grants totaling $822,137 through the US Federal Government’s Qualifying Therapeutic Discovery Project.


    The Qualifying Therapeutic Discovery Project grants are designed for qualified biotechnology companies with fewer than 250 employees that demonstrate the potential to develop new therapies to treat chronic conditions or unmet medical needs; reduce long-term health care costs in the United States; or significantly advance the goal of curing cancer within 30 years.


    Enacted as part of the Patient Protection and Affordable Care Act of 2010, the program reimburses up to 50% of investments in qualifying projects in 2009 and 2010.


    Rexahn’s President and Chief Operating Officer, Mr. Rick Soni, noted, “We are very pleased to receive the grants for all four applications we submitted. The award will further strengthen Rexahn’s financial position as we advance our drug development projects for cancers, depression, and erectile dysfunction”.


    Rexahn Projects Receiving Grants


    Anti-Cancer Drugs


    Rexahn is developing anti-cancer drugs to address the unmet needs of cancer patients. Archexin®, Rexahn’s lead candidate, is a unique, single targeted inhibitor of the AKT1 mRNA, presently in development for the treatment of advanced pancreatic cancer in combination with gemcitabine – potentially offering efficacy and tolerability benefits over present combination therapies. Preliminary results from this Phase 2 trial are expected in Q2 2011. Archexin has further potential in ovarian and stomach cancer, renal cell carcinoma, glioblastoma, which all orphan drug designation granted by the FDA, and prostate cancer. Among Rexahn’s other oncology candidates, RX-3117 is an anti-metabolite nucleoside with superior potency to gemcitabine in cancer animal models. RX-5902 is a new chemical entity (NCE), small molecule, micro tubule assembly inhibitor with potential multi mechanisms, presently in preclinical development for melanoma, and other solid and drug resistant tumors, in both oral and IV formulations. Both of these compounds are approximately 12 months away from IND filing.


    Serdaxin®


    Serdaxin is presently in clinical development for Major Depressive Disorder, and may work as a dual enhancer of serotonin and dopamine in the brain through a novel mechanism of action. In Rexahn’s Phase IIa, proof of concept study, Serdaxin showed numerical differences versus placebo for response and remission rates, as well as significance in the severe patient population versus placebo. The trial also demonstrated Serdaxin to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressants. Rexahn is moving forward with a larger phase II clinical trial, involving approximately 300 subjects using an independent central rater to reduce bias associated with depression trials. Preliminary results are expected in Q4 2011. Additionally, Serdaxin has shown neuroprotective potential in animals treated with neurotoxins, and may have important applications in the treatment of human neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer disease (AD). Moreover, animal model studies also suggest that Serdaxin reduces aggressive behavior and relieves anxiety.


    Zoraxel™


    Zoraxel is a unique CNS acting erectile dysfunction treatment, which works within 1 hour from administration, potentially without the safety concerns associated with PDE-5 inhibitors. In a proof of concept study, Zoraxel had a consistent improvement in IIEF-EF (International Index of Erectile Function) scores at the highest dose, 15 mg and also demonstrated Zoraxel’s excellent safety and tolerability profile. Rexahn recently announced plans for a large Phase II study that will assess Zoraxel’s efficacy in approx. 225 male subjects with ED. Preliminary data is expected to be available in Q3 2011.



    Poly-HPMA System for Drug Delivery


    Rexahn’s HPMA co-polymer system may provide an alternative and novel method of cancer targeting. The system works by conjugating cytotoxic anti-cancer drugs to a polymer backbone with a ligand to target cancer cells. Potentially this type of targeting will allow delivery of drugs directly into cancer cells to avoid damage to healthy non-target tissue.



    [Blocked Image: http://i54.tinypic.com/2zyarn7.jpg]

    Hot Pharma Stocks / Ideen / Blockbuster

    AVNR, JAZZ, ALKS, SNTS, ASTM, RNN.




    RNN sieht bärisch aus und kein volumen =

    im moment kein interesse. aber 31.12.2010 ist definitiv ein datum

    das wir uns für RNN merken werden

    und die Aktie bis dahin verfolgt wird! :roll:


    runter gehts auf 0.75$ rauf gehts auf 1.40$ im Moment.

    Hot Pharma Stocks / Ideen / Blockbuster

    hm RNN hat 20/50/100/200 MA am freitag überschritten, ich kann mir vorstellen das der trend so weiter geht


    etwaige news zu den 4 terminen könnten unvorbereitet einschlagen.. Viel zeit bleibt nicht mehr bis zum 31.12

    Hot Pharma Stocks / Ideen / Blockbuster

    b00n wrote:

    Quote
    hm RNN hat 20/50/100/200 MA am freitag überschritten, ich kann mir vorstellen das der trend so weiter geht

    etwaige news zu den 4 terminen könnten unvorbereitet einschlagen.. Viel zeit bleibt nicht mehr bis zum 31.12


    was für einen Zeitrahmen benutzt du im chart?


    200 Tage MA ist bei 1.38$ im Tageschart.


    [Blocked Image: http://img121.imageshack.us/img121/6531/rnn.th.png]

    Hot Pharma Stocks / Ideen / Blockbuster

    b00n wrote:

    Quote
    hab einen zu kurzen verwendet.


    müsste so ungefähr der 15 min gewesen sein. 30 min chart 200 Tage MA ist bei 1.13$ lol.

    allgemien in chart hat sich ne hammer candle geformt, RNN müsste auch jetzt kurzzeitig mal hoch spicken.


    31.12.2010, die haben jo sehr viele medis in der pipeline für dieses datum.

    Hot Pharma Stocks / Ideen / Blockbuster

    b00n wrote:

    Quote
    brrb wünsche alln guten wochenstart und happy trading

    mal sehn was bernankes druckerei bringt :)


    jop jop wünsche auch guten wochenstart. :)




    SNTS 3.34$


    Santarus, Inc. Announces Positive Top-Line Results In E.U. Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis


    Quote:

    Quote
    Santarus, Inc. announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo (p=0.0047) in achieving clinical remission as measured by the ulcerative colitis disease activity index (UCDAI) score after eight weeks of treatment. This second budesonide MMX Phase III clinical study was conducted in Europe in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals. As specified in the statistical analysis plans that were submitted to the FDA for both Phase III studies, a p-value of 0.025 was required to achieve statistical significance for the comparison of each budesonide MMX dosage strength (9 mg and 6 mg) with placebo. The intent-to-treat (ITT) population was pre-defined in the statistical analysis plan as all randomized patients who received at least one dose of a study drug, excluding patients with normal histology at baseline as determined by biopsy, Good Clinical Practice (GCP) violations or major entry criteria violations. The top-line study results indicate that budesonide MMX 9 mg and 6 mg were generally well tolerated and the frequency of treatment related adverse events was similar across all treatment groups.


    http://www.reuters.com/finance…&timestamp=20101108060000




    http://www.google.com/finance?q=NASDAQ:SNTS